Patients with thrombotic antiphospholipid syndrome appear better treated with a vitamin K antagonist such as warfarin, rather than a direct oral anticoagulant, a new meta-analysis suggests.
The largest study to date to look at this issue has actually found a lower rate of symptomatic intracerebral hemorrhage in patients on DOACs receiving thrombolysis than those not taking anticoagulants.